Back to today’s briefing

Story perspectives

Argenx, Unnatural Products Partner for $1.5B Peptide Innovation

7/2/2025

31 5

Summary

Story summary

Argenx has joined forces with Unnatural Products to innovate oral macrocyclic peptides, targeting inflammatory and immunological disorders. This groundbreaking partnership, valued at up to $1.5 billion, promises upfront payments and R&D support, paving the way for stable, once-daily pills that could transform treatment options for countless patients.

1 of 1

Story summary

Argenx has joined forces with Unnatural Products to innovate oral macrocyclic peptides, targeting inflammatory and immunological disorders. This groundbreaking partnership, valued at up to $1.5 billion, promises upfront payments and R&D support, paving the way for stable, once-daily pills that could transform treatment options for countless patients.